Summary

The global Kidney Cancer Drugs market size is predicted to grow from US$ 4511 million in 2025 to US$ 5861 million in 2031; it is expected to grow at a CAGR of 4.5% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.
Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.
LP Information, Inc. (LPI) ' newest research report, the “Kidney Cancer Drugs Industry Forecast” looks at past sales and reviews total world Kidney Cancer Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Kidney Cancer Drugs sales for 2025 through 2031. With Kidney Cancer Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Kidney Cancer Drugs industry.
This Insight Report provides a comprehensive analysis of the global Kidney Cancer Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Kidney Cancer Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Kidney Cancer Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Kidney Cancer Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Kidney Cancer Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Kidney Cancer Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)
Segmentation by Application:
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bayer
Roche
GlaxoSmithKline
Novartis
Pfizer
Abbott Laboratories
Active Biotech
Amgen
Argos Therapeutics
ArQule
AVEO Pharmaceuticals
Bionomics
Bristol-Myers Squibb
Cerulean Pharma
Exelixis
Genentech
immatics biotechnologies
Immunicum
Ono Pharmaceutical
Onyx Therapeutics
Oxford BioMedica
Prometheus Laboratories
Seattle Genetics
Taiwan Liposome
Tracon Pharmaceuticals
Wilex
Key Questions Addressed in this Report
What is the 10-year outlook for the global Kidney Cancer Drugs market?
What factors are driving Kidney Cancer Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Kidney Cancer Drugs market opportunities vary by end market size?
How does Kidney Cancer Drugs break out by Type, by Application?

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Kidney Cancer Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Kidney Cancer Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Kidney Cancer Drugs by Country/Region, 2020, 2024 & 2031
2.2 Kidney Cancer Drugs Segment by Type
2.2.1 Angiogenesis Inhibitors
2.2.2 mTOR Inhibitors
2.2.3 Monoclonal Antibodies
2.2.4 Cytokine Immunotherapy (IL-2)
2.3 Kidney Cancer Drugs Sales by Type
2.3.1 Global Kidney Cancer Drugs Sales Market Share by Type (2020-2025)
2.3.2 Global Kidney Cancer Drugs Revenue and Market Share by Type (2020-2025)
2.3.3 Global Kidney Cancer Drugs Sale Price by Type (2020-2025)
2.4 Kidney Cancer Drugs Segment by Application
2.4.1 Renal Cell Carcinoma (RCC)
2.4.2 Transitional Cell Carcinoma (TCC)
2.5 Kidney Cancer Drugs Sales by Application
2.5.1 Global Kidney Cancer Drugs Sale Market Share by Application (2020-2025)
2.5.2 Global Kidney Cancer Drugs Revenue and Market Share by Application (2020-2025)
2.5.3 Global Kidney Cancer Drugs Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Kidney Cancer Drugs Breakdown Data by Company
3.1.1 Global Kidney Cancer Drugs Annual Sales by Company (2020-2025)
3.1.2 Global Kidney Cancer Drugs Sales Market Share by Company (2020-2025)
3.2 Global Kidney Cancer Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global Kidney Cancer Drugs Revenue by Company (2020-2025)
3.2.2 Global Kidney Cancer Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Kidney Cancer Drugs Sale Price by Company
3.4 Key Manufacturers Kidney Cancer Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Kidney Cancer Drugs Product Location Distribution
3.4.2 Players Kidney Cancer Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Kidney Cancer Drugs by Geographic Region
4.1 World Historic Kidney Cancer Drugs Market Size by Geographic Region (2020-2025)
4.1.1 Global Kidney Cancer Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Kidney Cancer Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Kidney Cancer Drugs Market Size by Country/Region (2020-2025)
4.2.1 Global Kidney Cancer Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Kidney Cancer Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Kidney Cancer Drugs Sales Growth
4.4 APAC Kidney Cancer Drugs Sales Growth
4.5 Europe Kidney Cancer Drugs Sales Growth
4.6 Middle East & Africa Kidney Cancer Drugs Sales Growth
5 Americas
5.1 Americas Kidney Cancer Drugs Sales by Country
5.1.1 Americas Kidney Cancer Drugs Sales by Country (2020-2025)
5.1.2 Americas Kidney Cancer Drugs Revenue by Country (2020-2025)
5.2 Americas Kidney Cancer Drugs Sales by Type (2020-2025)
5.3 Americas Kidney Cancer Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Kidney Cancer Drugs Sales by Region
6.1.1 APAC Kidney Cancer Drugs Sales by Region (2020-2025)
6.1.2 APAC Kidney Cancer Drugs Revenue by Region (2020-2025)
6.2 APAC Kidney Cancer Drugs Sales by Type (2020-2025)
6.3 APAC Kidney Cancer Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Kidney Cancer Drugs by Country
7.1.1 Europe Kidney Cancer Drugs Sales by Country (2020-2025)
7.1.2 Europe Kidney Cancer Drugs Revenue by Country (2020-2025)
7.2 Europe Kidney Cancer Drugs Sales by Type (2020-2025)
7.3 Europe Kidney Cancer Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Kidney Cancer Drugs by Country
8.1.1 Middle East & Africa Kidney Cancer Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Kidney Cancer Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Kidney Cancer Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Kidney Cancer Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Kidney Cancer Drugs
10.3 Manufacturing Process Analysis of Kidney Cancer Drugs
10.4 Industry Chain Structure of Kidney Cancer Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Kidney Cancer Drugs Distributors
11.3 Kidney Cancer Drugs Customer
12 World Forecast Review for Kidney Cancer Drugs by Geographic Region
12.1 Global Kidney Cancer Drugs Market Size Forecast by Region
12.1.1 Global Kidney Cancer Drugs Forecast by Region (2026-2031)
12.1.2 Global Kidney Cancer Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Kidney Cancer Drugs Forecast by Type (2026-2031)
12.7 Global Kidney Cancer Drugs Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Bayer
13.1.1 Bayer Company Information
13.1.2 Bayer Kidney Cancer Drugs Product Portfolios and Specifications
13.1.3 Bayer Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Bayer Main Business Overview
13.1.5 Bayer Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche Kidney Cancer Drugs Product Portfolios and Specifications
13.2.3 Roche Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 GlaxoSmithKline
13.3.1 GlaxoSmithKline Company Information
13.3.2 GlaxoSmithKline Kidney Cancer Drugs Product Portfolios and Specifications
13.3.3 GlaxoSmithKline Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 GlaxoSmithKline Main Business Overview
13.3.5 GlaxoSmithKline Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Kidney Cancer Drugs Product Portfolios and Specifications
13.4.3 Novartis Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Pfizer
13.5.1 Pfizer Company Information
13.5.2 Pfizer Kidney Cancer Drugs Product Portfolios and Specifications
13.5.3 Pfizer Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Pfizer Main Business Overview
13.5.5 Pfizer Latest Developments
13.6 Abbott Laboratories
13.6.1 Abbott Laboratories Company Information
13.6.2 Abbott Laboratories Kidney Cancer Drugs Product Portfolios and Specifications
13.6.3 Abbott Laboratories Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Abbott Laboratories Main Business Overview
13.6.5 Abbott Laboratories Latest Developments
13.7 Active Biotech
13.7.1 Active Biotech Company Information
13.7.2 Active Biotech Kidney Cancer Drugs Product Portfolios and Specifications
13.7.3 Active Biotech Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Active Biotech Main Business Overview
13.7.5 Active Biotech Latest Developments
13.8 Amgen
13.8.1 Amgen Company Information
13.8.2 Amgen Kidney Cancer Drugs Product Portfolios and Specifications
13.8.3 Amgen Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Amgen Main Business Overview
13.8.5 Amgen Latest Developments
13.9 Argos Therapeutics
13.9.1 Argos Therapeutics Company Information
13.9.2 Argos Therapeutics Kidney Cancer Drugs Product Portfolios and Specifications
13.9.3 Argos Therapeutics Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Argos Therapeutics Main Business Overview
13.9.5 Argos Therapeutics Latest Developments
13.10 ArQule
13.10.1 ArQule Company Information
13.10.2 ArQule Kidney Cancer Drugs Product Portfolios and Specifications
13.10.3 ArQule Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 ArQule Main Business Overview
13.10.5 ArQule Latest Developments
13.11 AVEO Pharmaceuticals
13.11.1 AVEO Pharmaceuticals Company Information
13.11.2 AVEO Pharmaceuticals Kidney Cancer Drugs Product Portfolios and Specifications
13.11.3 AVEO Pharmaceuticals Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 AVEO Pharmaceuticals Main Business Overview
13.11.5 AVEO Pharmaceuticals Latest Developments
13.12 Bionomics
13.12.1 Bionomics Company Information
13.12.2 Bionomics Kidney Cancer Drugs Product Portfolios and Specifications
13.12.3 Bionomics Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Bionomics Main Business Overview
13.12.5 Bionomics Latest Developments
13.13 Bristol-Myers Squibb
13.13.1 Bristol-Myers Squibb Company Information
13.13.2 Bristol-Myers Squibb Kidney Cancer Drugs Product Portfolios and Specifications
13.13.3 Bristol-Myers Squibb Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Bristol-Myers Squibb Main Business Overview
13.13.5 Bristol-Myers Squibb Latest Developments
13.14 Cerulean Pharma
13.14.1 Cerulean Pharma Company Information
13.14.2 Cerulean Pharma Kidney Cancer Drugs Product Portfolios and Specifications
13.14.3 Cerulean Pharma Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Cerulean Pharma Main Business Overview
13.14.5 Cerulean Pharma Latest Developments
13.15 Exelixis
13.15.1 Exelixis Company Information
13.15.2 Exelixis Kidney Cancer Drugs Product Portfolios and Specifications
13.15.3 Exelixis Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Exelixis Main Business Overview
13.15.5 Exelixis Latest Developments
13.16 Genentech
13.16.1 Genentech Company Information
13.16.2 Genentech Kidney Cancer Drugs Product Portfolios and Specifications
13.16.3 Genentech Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Genentech Main Business Overview
13.16.5 Genentech Latest Developments
13.17 immatics biotechnologies
13.17.1 immatics biotechnologies Company Information
13.17.2 immatics biotechnologies Kidney Cancer Drugs Product Portfolios and Specifications
13.17.3 immatics biotechnologies Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 immatics biotechnologies Main Business Overview
13.17.5 immatics biotechnologies Latest Developments
13.18 Immunicum
13.18.1 Immunicum Company Information
13.18.2 Immunicum Kidney Cancer Drugs Product Portfolios and Specifications
13.18.3 Immunicum Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Immunicum Main Business Overview
13.18.5 Immunicum Latest Developments
13.19 Ono Pharmaceutical
13.19.1 Ono Pharmaceutical Company Information
13.19.2 Ono Pharmaceutical Kidney Cancer Drugs Product Portfolios and Specifications
13.19.3 Ono Pharmaceutical Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Ono Pharmaceutical Main Business Overview
13.19.5 Ono Pharmaceutical Latest Developments
13.20 Onyx Therapeutics
13.20.1 Onyx Therapeutics Company Information
13.20.2 Onyx Therapeutics Kidney Cancer Drugs Product Portfolios and Specifications
13.20.3 Onyx Therapeutics Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Onyx Therapeutics Main Business Overview
13.20.5 Onyx Therapeutics Latest Developments
13.21 Oxford BioMedica
13.21.1 Oxford BioMedica Company Information
13.21.2 Oxford BioMedica Kidney Cancer Drugs Product Portfolios and Specifications
13.21.3 Oxford BioMedica Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.21.4 Oxford BioMedica Main Business Overview
13.21.5 Oxford BioMedica Latest Developments
13.22 Prometheus Laboratories
13.22.1 Prometheus Laboratories Company Information
13.22.2 Prometheus Laboratories Kidney Cancer Drugs Product Portfolios and Specifications
13.22.3 Prometheus Laboratories Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.22.4 Prometheus Laboratories Main Business Overview
13.22.5 Prometheus Laboratories Latest Developments
13.23 Seattle Genetics
13.23.1 Seattle Genetics Company Information
13.23.2 Seattle Genetics Kidney Cancer Drugs Product Portfolios and Specifications
13.23.3 Seattle Genetics Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.23.4 Seattle Genetics Main Business Overview
13.23.5 Seattle Genetics Latest Developments
13.24 Taiwan Liposome
13.24.1 Taiwan Liposome Company Information
13.24.2 Taiwan Liposome Kidney Cancer Drugs Product Portfolios and Specifications
13.24.3 Taiwan Liposome Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.24.4 Taiwan Liposome Main Business Overview
13.24.5 Taiwan Liposome Latest Developments
13.25 Tracon Pharmaceuticals
13.25.1 Tracon Pharmaceuticals Company Information
13.25.2 Tracon Pharmaceuticals Kidney Cancer Drugs Product Portfolios and Specifications
13.25.3 Tracon Pharmaceuticals Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.25.4 Tracon Pharmaceuticals Main Business Overview
13.25.5 Tracon Pharmaceuticals Latest Developments
13.26 Wilex
13.26.1 Wilex Company Information
13.26.2 Wilex Kidney Cancer Drugs Product Portfolios and Specifications
13.26.3 Wilex Kidney Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.26.4 Wilex Main Business Overview
13.26.5 Wilex Latest Developments
14 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Kidney Cancer Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Kidney Cancer Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Angiogenesis Inhibitors
Table 4. Major Players of mTOR Inhibitors
Table 5. Major Players of Monoclonal Antibodies
Table 6. Major Players of Cytokine Immunotherapy (IL-2)
Table 7. Global Kidney Cancer Drugs Sales by Type (2020-2025) & (K Units)
Table 8. Global Kidney Cancer Drugs Sales Market Share by Type (2020-2025)
Table 9. Global Kidney Cancer Drugs Revenue by Type (2020-2025) & ($ million)
Table 10. Global Kidney Cancer Drugs Revenue Market Share by Type (2020-2025)
Table 11. Global Kidney Cancer Drugs Sale Price by Type (2020-2025) & (USD/Unit)
Table 12. Global Kidney Cancer Drugs Sale by Application (2020-2025) & (K Units)
Table 13. Global Kidney Cancer Drugs Sale Market Share by Application (2020-2025)
Table 14. Global Kidney Cancer Drugs Revenue by Application (2020-2025) & ($ million)
Table 15. Global Kidney Cancer Drugs Revenue Market Share by Application (2020-2025)
Table 16. Global Kidney Cancer Drugs Sale Price by Application (2020-2025) & (USD/Unit)
Table 17. Global Kidney Cancer Drugs Sales by Company (2020-2025) & (K Units)
Table 18. Global Kidney Cancer Drugs Sales Market Share by Company (2020-2025)
Table 19. Global Kidney Cancer Drugs Revenue by Company (2020-2025) & ($ millions)
Table 20. Global Kidney Cancer Drugs Revenue Market Share by Company (2020-2025)
Table 21. Global Kidney Cancer Drugs Sale Price by Company (2020-2025) & (USD/Unit)
Table 22. Key Manufacturers Kidney Cancer Drugs Producing Area Distribution and Sales Area
Table 23. Players Kidney Cancer Drugs Products Offered
Table 24. Kidney Cancer Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Kidney Cancer Drugs Sales by Geographic Region (2020-2025) & (K Units)
Table 28. Global Kidney Cancer Drugs Sales Market Share Geographic Region (2020-2025)
Table 29. Global Kidney Cancer Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global Kidney Cancer Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global Kidney Cancer Drugs Sales by Country/Region (2020-2025) & (K Units)
Table 32. Global Kidney Cancer Drugs Sales Market Share by Country/Region (2020-2025)
Table 33. Global Kidney Cancer Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global Kidney Cancer Drugs Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas Kidney Cancer Drugs Sales by Country (2020-2025) & (K Units)
Table 36. Americas Kidney Cancer Drugs Sales Market Share by Country (2020-2025)
Table 37. Americas Kidney Cancer Drugs Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas Kidney Cancer Drugs Sales by Type (2020-2025) & (K Units)
Table 39. Americas Kidney Cancer Drugs Sales by Application (2020-2025) & (K Units)
Table 40. APAC Kidney Cancer Drugs Sales by Region (2020-2025) & (K Units)
Table 41. APAC Kidney Cancer Drugs Sales Market Share by Region (2020-2025)
Table 42. APAC Kidney Cancer Drugs Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC Kidney Cancer Drugs Sales by Type (2020-2025) & (K Units)
Table 44. APAC Kidney Cancer Drugs Sales by Application (2020-2025) & (K Units)
Table 45. Europe Kidney Cancer Drugs Sales by Country (2020-2025) & (K Units)
Table 46. Europe Kidney Cancer Drugs Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe Kidney Cancer Drugs Sales by Type (2020-2025) & (K Units)
Table 48. Europe Kidney Cancer Drugs Sales by Application (2020-2025) & (K Units)
Table 49. Middle East & Africa Kidney Cancer Drugs Sales by Country (2020-2025) & (K Units)
Table 50. Middle East & Africa Kidney Cancer Drugs Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa Kidney Cancer Drugs Sales by Type (2020-2025) & (K Units)
Table 52. Middle East & Africa Kidney Cancer Drugs Sales by Application (2020-2025) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Kidney Cancer Drugs
Table 54. Key Market Challenges & Risks of Kidney Cancer Drugs
Table 55. Key Industry Trends of Kidney Cancer Drugs
Table 56. Kidney Cancer Drugs Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Kidney Cancer Drugs Distributors List
Table 59. Kidney Cancer Drugs Customer List
Table 60. Global Kidney Cancer Drugs Sales Forecast by Region (2026-2031) & (K Units)
Table 61. Global Kidney Cancer Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 62. Americas Kidney Cancer Drugs Sales Forecast by Country (2026-2031) & (K Units)
Table 63. Americas Kidney Cancer Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 64. APAC Kidney Cancer Drugs Sales Forecast by Region (2026-2031) & (K Units)
Table 65. APAC Kidney Cancer Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 66. Europe Kidney Cancer Drugs Sales Forecast by Country (2026-2031) & (K Units)
Table 67. Europe Kidney Cancer Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa Kidney Cancer Drugs Sales Forecast by Country (2026-2031) & (K Units)
Table 69. Middle East & Africa Kidney Cancer Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 70. Global Kidney Cancer Drugs Sales Forecast by Type (2026-2031) & (K Units)
Table 71. Global Kidney Cancer Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 72. Global Kidney Cancer Drugs Sales Forecast by Application (2026-2031) & (K Units)
Table 73. Global Kidney Cancer Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 74. Bayer Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 75. Bayer Kidney Cancer Drugs Product Portfolios and Specifications
Table 76. Bayer Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77. Bayer Main Business
Table 78. Bayer Latest Developments
Table 79. Roche Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 80. Roche Kidney Cancer Drugs Product Portfolios and Specifications
Table 81. Roche Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 82. Roche Main Business
Table 83. Roche Latest Developments
Table 84. GlaxoSmithKline Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. GlaxoSmithKline Kidney Cancer Drugs Product Portfolios and Specifications
Table 86. GlaxoSmithKline Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 87. GlaxoSmithKline Main Business
Table 88. GlaxoSmithKline Latest Developments
Table 89. Novartis Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 90. Novartis Kidney Cancer Drugs Product Portfolios and Specifications
Table 91. Novartis Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 92. Novartis Main Business
Table 93. Novartis Latest Developments
Table 94. Pfizer Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. Pfizer Kidney Cancer Drugs Product Portfolios and Specifications
Table 96. Pfizer Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 97. Pfizer Main Business
Table 98. Pfizer Latest Developments
Table 99. Abbott Laboratories Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Abbott Laboratories Kidney Cancer Drugs Product Portfolios and Specifications
Table 101. Abbott Laboratories Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 102. Abbott Laboratories Main Business
Table 103. Abbott Laboratories Latest Developments
Table 104. Active Biotech Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 105. Active Biotech Kidney Cancer Drugs Product Portfolios and Specifications
Table 106. Active Biotech Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 107. Active Biotech Main Business
Table 108. Active Biotech Latest Developments
Table 109. Amgen Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 110. Amgen Kidney Cancer Drugs Product Portfolios and Specifications
Table 111. Amgen Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 112. Amgen Main Business
Table 113. Amgen Latest Developments
Table 114. Argos Therapeutics Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 115. Argos Therapeutics Kidney Cancer Drugs Product Portfolios and Specifications
Table 116. Argos Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 117. Argos Therapeutics Main Business
Table 118. Argos Therapeutics Latest Developments
Table 119. ArQule Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 120. ArQule Kidney Cancer Drugs Product Portfolios and Specifications
Table 121. ArQule Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 122. ArQule Main Business
Table 123. ArQule Latest Developments
Table 124. AVEO Pharmaceuticals Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 125. AVEO Pharmaceuticals Kidney Cancer Drugs Product Portfolios and Specifications
Table 126. AVEO Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 127. AVEO Pharmaceuticals Main Business
Table 128. AVEO Pharmaceuticals Latest Developments
Table 129. Bionomics Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 130. Bionomics Kidney Cancer Drugs Product Portfolios and Specifications
Table 131. Bionomics Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 132. Bionomics Main Business
Table 133. Bionomics Latest Developments
Table 134. Bristol-Myers Squibb Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 135. Bristol-Myers Squibb Kidney Cancer Drugs Product Portfolios and Specifications
Table 136. Bristol-Myers Squibb Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 137. Bristol-Myers Squibb Main Business
Table 138. Bristol-Myers Squibb Latest Developments
Table 139. Cerulean Pharma Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 140. Cerulean Pharma Kidney Cancer Drugs Product Portfolios and Specifications
Table 141. Cerulean Pharma Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 142. Cerulean Pharma Main Business
Table 143. Cerulean Pharma Latest Developments
Table 144. Exelixis Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 145. Exelixis Kidney Cancer Drugs Product Portfolios and Specifications
Table 146. Exelixis Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 147. Exelixis Main Business
Table 148. Exelixis Latest Developments
Table 149. Genentech Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 150. Genentech Kidney Cancer Drugs Product Portfolios and Specifications
Table 151. Genentech Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 152. Genentech Main Business
Table 153. Genentech Latest Developments
Table 154. immatics biotechnologies Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 155. immatics biotechnologies Kidney Cancer Drugs Product Portfolios and Specifications
Table 156. immatics biotechnologies Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 157. immatics biotechnologies Main Business
Table 158. immatics biotechnologies Latest Developments
Table 159. Immunicum Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 160. Immunicum Kidney Cancer Drugs Product Portfolios and Specifications
Table 161. Immunicum Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 162. Immunicum Main Business
Table 163. Immunicum Latest Developments
Table 164. Ono Pharmaceutical Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 165. Ono Pharmaceutical Kidney Cancer Drugs Product Portfolios and Specifications
Table 166. Ono Pharmaceutical Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 167. Ono Pharmaceutical Main Business
Table 168. Ono Pharmaceutical Latest Developments
Table 169. Onyx Therapeutics Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 170. Onyx Therapeutics Kidney Cancer Drugs Product Portfolios and Specifications
Table 171. Onyx Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 172. Onyx Therapeutics Main Business
Table 173. Onyx Therapeutics Latest Developments
Table 174. Oxford BioMedica Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 175. Oxford BioMedica Kidney Cancer Drugs Product Portfolios and Specifications
Table 176. Oxford BioMedica Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 177. Oxford BioMedica Main Business
Table 178. Oxford BioMedica Latest Developments
Table 179. Prometheus Laboratories Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 180. Prometheus Laboratories Kidney Cancer Drugs Product Portfolios and Specifications
Table 181. Prometheus Laboratories Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 182. Prometheus Laboratories Main Business
Table 183. Prometheus Laboratories Latest Developments
Table 184. Seattle Genetics Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 185. Seattle Genetics Kidney Cancer Drugs Product Portfolios and Specifications
Table 186. Seattle Genetics Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 187. Seattle Genetics Main Business
Table 188. Seattle Genetics Latest Developments
Table 189. Taiwan Liposome Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 190. Taiwan Liposome Kidney Cancer Drugs Product Portfolios and Specifications
Table 191. Taiwan Liposome Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 192. Taiwan Liposome Main Business
Table 193. Taiwan Liposome Latest Developments
Table 194. Tracon Pharmaceuticals Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 195. Tracon Pharmaceuticals Kidney Cancer Drugs Product Portfolios and Specifications
Table 196. Tracon Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 197. Tracon Pharmaceuticals Main Business
Table 198. Tracon Pharmaceuticals Latest Developments
Table 199. Wilex Basic Information, Kidney Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 200. Wilex Kidney Cancer Drugs Product Portfolios and Specifications
Table 201. Wilex Kidney Cancer Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 202. Wilex Main Business
Table 203. Wilex Latest Developments


List of Figures
Figure 1. Picture of Kidney Cancer Drugs
Figure 2. Kidney Cancer Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Kidney Cancer Drugs Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Kidney Cancer Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Kidney Cancer Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Kidney Cancer Drugs Sales Market Share by Country/Region (2024)
Figure 10. Kidney Cancer Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Angiogenesis Inhibitors
Figure 12. Product Picture of mTOR Inhibitors
Figure 13. Product Picture of Monoclonal Antibodies
Figure 14. Product Picture of Cytokine Immunotherapy (IL-2)
Figure 15. Global Kidney Cancer Drugs Sales Market Share by Type in 2025
Figure 16. Global Kidney Cancer Drugs Revenue Market Share by Type (2020-2025)
Figure 17. Kidney Cancer Drugs Consumed in Renal Cell Carcinoma (RCC)
Figure 18. Global Kidney Cancer Drugs Market: Renal Cell Carcinoma (RCC) (2020-2025) & (K Units)
Figure 19. Kidney Cancer Drugs Consumed in Transitional Cell Carcinoma (TCC)
Figure 20. Global Kidney Cancer Drugs Market: Transitional Cell Carcinoma (TCC) (2020-2025) & (K Units)
Figure 21. Global Kidney Cancer Drugs Sale Market Share by Application (2024)
Figure 22. Global Kidney Cancer Drugs Revenue Market Share by Application in 2025
Figure 23. Kidney Cancer Drugs Sales by Company in 2025 (K Units)
Figure 24. Global Kidney Cancer Drugs Sales Market Share by Company in 2025
Figure 25. Kidney Cancer Drugs Revenue by Company in 2025 ($ millions)
Figure 26. Global Kidney Cancer Drugs Revenue Market Share by Company in 2025
Figure 27. Global Kidney Cancer Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 28. Global Kidney Cancer Drugs Revenue Market Share by Geographic Region in 2025
Figure 29. Americas Kidney Cancer Drugs Sales 2020-2025 (K Units)
Figure 30. Americas Kidney Cancer Drugs Revenue 2020-2025 ($ millions)
Figure 31. APAC Kidney Cancer Drugs Sales 2020-2025 (K Units)
Figure 32. APAC Kidney Cancer Drugs Revenue 2020-2025 ($ millions)
Figure 33. Europe Kidney Cancer Drugs Sales 2020-2025 (K Units)
Figure 34. Europe Kidney Cancer Drugs Revenue 2020-2025 ($ millions)
Figure 35. Middle East & Africa Kidney Cancer Drugs Sales 2020-2025 (K Units)
Figure 36. Middle East & Africa Kidney Cancer Drugs Revenue 2020-2025 ($ millions)
Figure 37. Americas Kidney Cancer Drugs Sales Market Share by Country in 2025
Figure 38. Americas Kidney Cancer Drugs Revenue Market Share by Country (2020-2025)
Figure 39. Americas Kidney Cancer Drugs Sales Market Share by Type (2020-2025)
Figure 40. Americas Kidney Cancer Drugs Sales Market Share by Application (2020-2025)
Figure 41. United States Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 42. Canada Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 43. Mexico Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 44. Brazil Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. APAC Kidney Cancer Drugs Sales Market Share by Region in 2025
Figure 46. APAC Kidney Cancer Drugs Revenue Market Share by Region (2020-2025)
Figure 47. APAC Kidney Cancer Drugs Sales Market Share by Type (2020-2025)
Figure 48. APAC Kidney Cancer Drugs Sales Market Share by Application (2020-2025)
Figure 49. China Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 50. Japan Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 51. South Korea Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. Southeast Asia Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. India Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. Australia Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. China Taiwan Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. Europe Kidney Cancer Drugs Sales Market Share by Country in 2025
Figure 57. Europe Kidney Cancer Drugs Revenue Market Share by Country (2020-2025)
Figure 58. Europe Kidney Cancer Drugs Sales Market Share by Type (2020-2025)
Figure 59. Europe Kidney Cancer Drugs Sales Market Share by Application (2020-2025)
Figure 60. Germany Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 61. France Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 62. UK Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. Italy Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. Russia Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. Middle East & Africa Kidney Cancer Drugs Sales Market Share by Country (2020-2025)
Figure 66. Middle East & Africa Kidney Cancer Drugs Sales Market Share by Type (2020-2025)
Figure 67. Middle East & Africa Kidney Cancer Drugs Sales Market Share by Application (2020-2025)
Figure 68. Egypt Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 69. South Africa Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 70. Israel Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. Turkey Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. GCC Countries Kidney Cancer Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Kidney Cancer Drugs in 2025
Figure 74. Manufacturing Process Analysis of Kidney Cancer Drugs
Figure 75. Industry Chain Structure of Kidney Cancer Drugs
Figure 76. Channels of Distribution
Figure 77. Global Kidney Cancer Drugs Sales Market Forecast by Region (2026-2031)
Figure 78. Global Kidney Cancer Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 79. Global Kidney Cancer Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 80. Global Kidney Cancer Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 81. Global Kidney Cancer Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 82. Global Kidney Cancer Drugs Revenue Market Share Forecast by Application (2026-2031)